SCHEMBL3484969

SCHEMBL3484969

CCOC(=O)C(C)(C)Oc1ccccc1C(=O)c1ccc(C)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 3/20 0.51
PPARG P37231 3/20 0.51
FBP1 P09467 3/20 0.49
ALDH1A1 P00352 3/20 0.48
LMNA P02545 2/20 0.48
ELANE P08246 2/20 0.48
AKR1C3 P42330 1/20 0.47
ABCB1 P08183 1/20 0.46
TSHR P16473 2/20 0.45
ABCB11 O95342 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
HTR2A P28223 1/20 0.45
PMP22 Q01453 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.42
RAB9A P51151 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
STS P08842 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3484043 0.89 PPARA (0.48) PPARAPPARGFBP1ALDH1A1LMNA
SCHEMBL31745119 0.82 FBP1 (0.54) PPARAPPARGFBP1ALDH1A1LMNA
SCHEMBL11783788 0.81 FBP1 (0.53) PPARAPPARGFBP1ALDH1A1LMNA
SCHEMBL3485059 0.80 FBP1 (0.52) PPARAPPARGFBP1ALDH1A1LMNA
SCHEMBL3483995 0.79 PPARA (0.66) PPARAPPARGFBP1ALDH1A1LMNA
SCHEMBL7768349 0.79 ABCB1 (0.60) LMNAAKR1C3ABCB1CYP1A2CYP3A4
SCHEMBL4111678 0.77 FBP1 (0.58) PPARAPPARGFBP1TSHRABCB11
SCHEMBL12670823 0.76 FBP1 (0.56) PPARAPPARGFBP1LMNATSHR
SCHEMBL31745361 0.75 ALDH1A1 (0.51) PPARAPPARGFBP1ALDH1A1ELANE
SCHEMBL3484204 0.75 PPARG (0.55) PPARAPPARGFBP1LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004159-A1 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES GENFIT (FR) 2010-01-07 US disclosed
US-20100004159-A1 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES GENFIT (FR) 2010-01-07 US disclosed
US-20100004159-A1 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES GENFIT (FR) 2010-01-07 US disclosed
EP-2049107-A2 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATION AND USES Genfit (FR) 2009-04-22 EP disclosed
WO-2008012470-A2 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATION AND USES GENFIT (FR) 2008-01-31 WO disclosed
WO-2008012470-A2 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATION AND USES GENFIT (FR) 2008-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004159-A1 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES IPO5, PPIP5K2, IPO4 PPARA 1045/4885PPARG 422/4885FBP1 2382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.